Login
From:
Forbes
(Uncensored)
subscribe
GSK Inks $1.5 Billion Deal For CureVac’s mRNA Bird Flu, COVID And Seasonal Flu Vaccines
https://www.forbes.com/sites/roberthart/2024/07/03/gsk-secures-mrna-vaccines-for-bird-flu-covid-and-seasonal-flu-from-struggling-biotech-curevac/
links
backlinks
mRNA specialist CureVac, which struggled to compete with the likes of Pfizer, Moderna and BioNTech, said it will focus on developing mRNA cancer vaccines and will cut 30% of its staff.
Roast topics
Find topics
Roast it!
Roast topics
Find topics
Find it!
Roast topics
Find topics
Find it!
